The Office of the Director of National Intelligence released a catalog of more than 120 U.S.-funded laboratories operating in over 30 countries, reigniting scrutiny over the pandemic’s origins and the safety of gain‑of‑function work. at the same time, the Senate is moving a bill that would restrict the president’s ability to end intelligence sharing with Israel, a measure that has drawn sharp reactions on Capitol Hill.

ODNI Identifies 120 U.S.-Funded Labs in 30+ Nations

The ODNI disclosure lists over 120 facilities spread across more than 30 countries, many of which conduct research on highly contagious pathogens. According to the agency, several labs have engaged in or continue to perform gain‑of‑function experiments with limited oversight.. The agency’s updated guidance urges tighter monitoring of overseas biological research sites, emphasizing “the need for increased transparency and the need to curb federal support for certain pathogen research overseas.”

Senate Bill Would Limit President’s Power to Cut Israel Intelligence Sharing

A Senate‑drafted bill aims to prevent the president from unilaterally ending intelligence cooperation with Israel, a move that has sparked mixed responses from both parties. Proponents argue the legislation safeguards a key strategic partnership , while critics warn it could lock the United States into sharing sensitive data without adequate congressional oversight. The proposal is part of a broader debate over the balance of executive authority and legislative control of foreign intelligence.

Gain‑of‑Function Research Raises Ethical and Security Concerns

The ODNI report flags ethical, financial, and security worries tied to clinical trials at some of the identified labs. It notes that “many of these labs have engaged in or are currenlty engaging in research using hazardous and highly contagious pathogens, with little visibility or oversight.” The agency reiterates that the president has already taken “decisive action to end federal funding of such research around the world,” yet acknowledges that the issue remains “complex” and requires further work.

Jay Clayton’s Upcoming Confirmation Could Shape Intelligence Policy

The Senate has scheduled a confirmation hearing for Jay Clayton on June 17, with the possibility of him becoming the next Director of National Intelligence later this month. If confirmed, Clayton would inherit the task of navigating the biolab mapping effort, the contentious Israel‑sharing bill, and internal Senate disputes over leadership and surveillance authority. As the agency continues to map lab locations and pathogen inventories, his leadership could prove pivotal.

Unanswered Questions About Lab Oversight and Pandemic Origins

Key uncertainties remain: Which specific pathogens are housed in the newly identified labs, and what exact safeguards are in place? How will the Senate’s restriction on presidential authority affect real‑time intelligence sharing with Israel, especially in the context of emerging biological threats? The ODNI’s statement makes clear that “more work needs to be done to address the concerns surrounding gain‑of‑function research,” but concrete steps are still pending.